(S)-2-bromo-2-phenylacetic acid benzyl ester | 1063685-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-bromo-2-phenylacetic acid benzyl ester
• 英文别名: benzyl (2S)-2-bromo-2-phenylacetate
• CAS: 1063685-52-8
• 化学式: C₁₅H₁₃BrO₂
• 分子量: 305.171
• InChiKey: GCJIKSNIRBMITQ-AWEZNQCLSA-N

物化性质

• 沸点：
  371.9±27.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  benzyl 2-bromo-2-phenylacetate 在 水 作用下， 以 癸烷 为溶剂， 反应 1.33h， 生成 (S)-2-bromo-2-phenylacetic acid benzyl ester 、 (R)-2-bromo-2-phenylacetic acid 、 S-2-溴-2-苯基乙酸
  参考文献：
  名称：

  A variant of Yarrowia lipolytica lipase with improved activity and enantioselectivity for resolution of 2-bromo-arylacetic acid esters

  摘要：

  A variant of Lip2p lipase from Yarrowia lipolytica yeast was used for the resolution of 2-bromophenyl and o-tolyl acid esters, an important class of chemical intermediates for the pharmaceutical industry. In comparison with wild-type Lip2p, this variant, which contains one single amino acid change in the active site of the enzyme, V232A, displayed an enantioselectivity enhanced by one order of magnitude for the resolution of 2-bromo-phenylacetic acid ethyl ester (E-value increased from 5.5 to 59 for wild-type and V232A, respectively) and by fourfold for the resolution of 2-bromo-o-tolylacetic acid ethyl ester (going from an E-value of 27 to 111 for the wild-type and V232A, respectively). A remarkable increase in reaction velocity was also observed for both compounds, as a result of a significant gain in reactivity towards the favoured (S)-enantiomer (3- and 16-fold increase for 2-bromo-phenylacetic and -o-tolylacetic acid ethyl esters, respectively). These results demonstrate the key role of the V232 amino acid in enantiomer recognition and selectivity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.06.009

文献信息

• [EN] THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES À SUBSTITUTION THIOPHÈNE ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DES MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014110688A1

  公开（公告）日：2014-07-24

  Disclosed are novel Thiophene-Subsituted Tetracyclic Compounds of Formula (I). And pharmaceutically acceptable salts thereof, wherein A, A', R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one Thiophene-Subsituted Tetracyclic Compounds, and methods of using the Thiophene-Subsituted Tetracyclic Compounds for treating or preventing HCV infection in a patient are also disclosed.

  本发明涉及一种新颖的式(I)的噻吩取代四环化合物，以及其药学上可接受的盐，其中A、A'、R2、R3、R4和R5如本文所定义。还公开了包含至少一种噻吩取代四环化合物的组合物，以及使用这些噻吩取代四环化合物治疗或预防患者HCV感染的方法。
• [EN] THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES À SUBSTITUTION THIOPHÈNE ET LEURS MÉHODES D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014110706A1

  公开（公告）日：2014-07-24

  Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.

  式(I)的噻吩取代四环化合物及其药用可接受的盐，其中A、A'、R2、R3、R4和R5如本文所定义。还提供了包含至少一种噻吩取代四环化合物的组合物，以及使用这些噻吩取代四环化合物治疗或预防患者HCV感染的方法。
• THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160257697A1

  公开（公告）日：2016-09-08

  Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R 2 , R 3 , R 4 and R 5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.
• A variant of Yarrowia lipolytica lipase with improved activity and enantioselectivity for resolution of 2-bromo-arylacetic acid esters
  作者：Miguel Cancino、Philippe Bauchart、Georgina Sandoval、Jean-Marc Nicaud、Isabelle André、Valérie Dossat、Alain Marty

  DOI：10.1016/j.tetasy.2008.06.009

  日期：2008.7

  A variant of Lip2p lipase from Yarrowia lipolytica yeast was used for the resolution of 2-bromophenyl and o-tolyl acid esters, an important class of chemical intermediates for the pharmaceutical industry. In comparison with wild-type Lip2p, this variant, which contains one single amino acid change in the active site of the enzyme, V232A, displayed an enantioselectivity enhanced by one order of magnitude for the resolution of 2-bromo-phenylacetic acid ethyl ester (E-value increased from 5.5 to 59 for wild-type and V232A, respectively) and by fourfold for the resolution of 2-bromo-o-tolylacetic acid ethyl ester (going from an E-value of 27 to 111 for the wild-type and V232A, respectively). A remarkable increase in reaction velocity was also observed for both compounds, as a result of a significant gain in reactivity towards the favoured (S)-enantiomer (3- and 16-fold increase for 2-bromo-phenylacetic and -o-tolylacetic acid ethyl esters, respectively). These results demonstrate the key role of the V232 amino acid in enantiomer recognition and selectivity. (C) 2008 Elsevier Ltd. All rights reserved.